Updated Jul 16, 2026 · Last SEC filing 2026-07-08
Relay Therapeutics, Inc. (RLAY) has filed 14 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-08. 5 Form 8-K material event filings were reported by RLAY in the last 90 days. 5 Form 144 notices of proposed sale were filed for RLAY stock. InsiderAlpha tracks every RLAY SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001812364 |
|---|
| Form 4 filings (90d) | 14 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 5 |
| Latest Form 4 filing | 2026-07-08 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Patel Sanjiv | President and CEO | S — Open-market sale | 48.2K | $19.58 | $944K | SEC | |
| Bergstrom Donald A | President, R&D | S — Open-market sale | 8.7K | $18.71 | $162K | SEC | |
| Catinazzo Thomas | Chief Financial Officer | S — Open-market sale | 17.7K | $18.69 | $331K | SEC | |
| Patel Sanjiv | President and CEO | A — Grant or award | 3.1K | $6.95 | $21K | SEC | |
| Rahmer Peter | See remarks | A — Grant or award | 3.1K | $6.95 | $21K | SEC | |
| Rahmer Peter | See remarks | S — Open-market sale | 50.0K | $19.09 | $954K | SEC | |
| Bergstrom Donald A | President, R&D | M — Option exercise | 93.5K | $4.12 | $385K | SEC | |
| Catinazzo Thomas | Chief Financial Officer | M — Option exercise | 51.6K | $4.45 | $229K | SEC | |
| Catinazzo Thomas | Chief Financial Officer | S — Open-market sale | 61.6K | $16.97 | $1.04M | SEC | |
| Catinazzo Thomas | Chief Financial Officer | M — Option exercise | 56.3K | $5.04 | $284K | SEC | |
| Catinazzo Thomas | Chief Financial Officer | M — Option exercise | 61.6K | $5.22 | $321K | SEC | |
| Catinazzo Thomas | Chief Financial Officer | S — Open-market sale | 51.6K | $16.97 | $875K | SEC | |
| Catinazzo Thomas | Chief Financial Officer | S — Open-market sale | 17.7K | $17.01 | $301K | SEC | |
| Bergstrom Donald A | President, R&D | S — Open-market sale | 93.5K | $16.94 | $1.58M | SEC | |
| Catinazzo Thomas | Chief Financial Officer | S — Open-market sale | 56.3K | $16.97 | $956K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Relay Therapeutics, Inc. (RLAY). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Catinazzo Thomas | 12 | $4.57M |
| Bergstrom Donald A | 4 | $2.13M |
| Patel Sanjiv | 2 | $965K |
| Rahmer Peter | 2 | $976K |
| COATS LONNEL | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RLAY insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live RLAY dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.